메뉴 건너뛰기




Volumn , Issue , 2008, Pages 425-446

Building Virtual Human Populations: Assessing the Propagation of Genetic Variability in Drug Metabolism to Pharmacokinetics and Pharmacodynamics

Author keywords

ADME; Applications; Biosimulation; Drug metabolism; Interindividual variability; Modeling; Pharmacodynamics; Pharmacokinetics; Simulation; Virtual human populations

Indexed keywords


EID: 84889273248     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527622672.ch16     Document Type: Chapter
Times cited : (6)

References (56)
  • 1
    • 0035462130 scopus 로고    scopus 로고
    • From idea to market: the drug approval process
    • Lipsky, M.S. and Sharp, L.K.: From idea to market: the drug approval process. J Am Board Fam Pract 2001, 14:362-367.
    • (2001) J Am Board Fam Pract , vol.14 , pp. 362-367
    • Lipsky, M.S.1    Sharp, L.K.2
  • 2
    • 0003403775 scopus 로고
    • Clinical Pharmacokinetics: Concepts and Applications
    • Lippincott Williams & Wilkins
    • Rowland, M. and Tozer, T.N.: Clinical Pharmacokinetics: Concepts and Applications, Lippincott Williams & Wilkins, 1995.
    • (1995)
    • Rowland, M.1    Tozer, T.N.2
  • 3
    • 6944221357 scopus 로고    scopus 로고
    • Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios
    • Williams, J.A. et al.: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004, 32:1201-1208.
    • (2004) Drug Metab Dispos , vol.32 , pp. 1201-1208
    • Williams, J.A.1
  • 4
    • 0000197885 scopus 로고
    • The hemolytic effect of primaquine and related compounds: a review
    • Beutler, E.: The hemolytic effect of primaquine and related compounds: a review. Blood 1959, 14:103-139.
    • (1959) Blood , vol.14 , pp. 103-139
    • Beutler, E.1
  • 5
    • 0142022251 scopus 로고
    • On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers
    • Kalow, W. and Staron, N.: On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. Can J Biochem Physiol 1957, 35:1305-1320.
    • (1957) Can J Biochem Physiol , vol.35 , pp. 1305-1320
    • Kalow, W.1    Staron, N.2
  • 6
    • 0035721949 scopus 로고    scopus 로고
    • Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy
    • Ingelman-Sundberg, M.: Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001, 250:186-200.
    • (2001) J Intern Med , vol.250 , pp. 186-200
    • Ingelman-Sundberg, M.1
  • 7
    • 0017599469 scopus 로고
    • Frequency distribution of free warfarin and free phenytoin fraction values in serum of healthy human adults
    • Yacobi, A. et al.: Frequency distribution of free warfarin and free phenytoin fraction values in serum of healthy human adults. Clin Pharmacol Ther 1977, 21:283-286.
    • (1977) Clin Pharmacol Ther , vol.21 , pp. 283-286
    • Yacobi, A.1
  • 8
    • 0031472588 scopus 로고    scopus 로고
    • Role of pharmacokinetics and metabolism in drug discovery and development
    • Lin, J.H. and Lu, A.Y.: Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997, 49:403-449.
    • (1997) Pharmacol Rev , vol.49 , pp. 403-449
    • Lin, J.H.1    Lu, A.Y.2
  • 9
    • 0026254621 scopus 로고
    • Genotype or Phenotype: the Definition of a Pharmacogenetic Polymorphism
    • Meyer, U.A.: Genotype or Phenotype: the Definition of a Pharmacogenetic Polymorphism. Pharmacogenetics 1991, 1:66-67.
    • (1991) Pharmacogenetics , vol.1 , pp. 66-67
    • Meyer, U.A.1
  • 10
    • 0035011217 scopus 로고    scopus 로고
    • Drug disposition: to phenotype or genotype
    • Dickins, M. and Tucker, G.T.: Drug disposition: to phenotype or genotype. Int J Pharm Med 2001, 15:70-73.
    • (2001) Int J Pharm Med , vol.15 , pp. 70-73
    • Dickins, M.1    Tucker, G.T.2
  • 11
    • 0004037003 scopus 로고    scopus 로고
    • Applied Biopharmaceutics and Pharmacokinetics
    • Appleton and Lange
    • Shargel, L. and Yu, A.B.C.: Applied Biopharmaceutics and Pharmacokinetics, Appleton and Lange, 1999.
    • (1999)
    • Shargel, L.1    Yu, A.B.C.2
  • 12
    • 33745231761 scopus 로고    scopus 로고
    • Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans
    • Yamashiro, W. et al.: Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 2006, 34:1247-1254.
    • (2006) Drug Metab Dispos , vol.34 , pp. 1247-1254
    • Yamashiro, W.1
  • 13
    • 0033953714 scopus 로고    scopus 로고
    • The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma
    • Liggett, S.B.: The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma. J Allergy Clin Immunol 2000, 105:S487-S492.
    • (2000) J Allergy Clin Immunol , vol.105
    • Liggett, S.B.1
  • 14
    • 0036154953 scopus 로고    scopus 로고
    • A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans
    • Hollt, V.: A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans. Pharmacogenetics 2002, 12:1-2.
    • (2002) Pharmacogenetics , vol.12 , pp. 1-2
    • Hollt, V.1
  • 15
    • 0036152705 scopus 로고    scopus 로고
    • The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine
    • Lotsch, J. et al.: The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002, 12:3-9.
    • (2002) Pharmacogenetics , vol.12 , pp. 3-9
    • Lotsch, J.1
  • 16
    • 0141538180 scopus 로고    scopus 로고
    • Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges
    • Johnson, J.A. and Lima, J.J.: Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 2003, 13:525-534.
    • (2003) Pharmacogenetics , vol.13 , pp. 525-534
    • Johnson, J.A.1    Lima, J.J.2
  • 17
    • 0036848427 scopus 로고    scopus 로고
    • Hello Drug Discovery, I am from insilico, take me to your president
    • Smith, D.A.: Hello Drug Discovery, I am from insilico, take me to your president. Drug Discov Today 2002, 7:1080-1081.
    • (2002) Drug Discov Today , vol.7 , pp. 1080-1081
    • Smith, D.A.1
  • 18
    • 0033996876 scopus 로고    scopus 로고
    • Clinical trial simulation in drug development
    • Bonate, P.L.: Clinical trial simulation in drug development. Pharm Res 2000, 17:252-256.
    • (2000) Pharm Res , vol.17 , pp. 252-256
    • Bonate, P.L.1
  • 19
    • 0035424803 scopus 로고    scopus 로고
    • Modelling and simulation in clinical drug development
    • Rooney, K.F. et al.: Modelling and simulation in clinical drug development. Drug Discov Today 2001, 6:802-806.
    • (2001) Drug Discov Today , vol.6 , pp. 802-806
    • Rooney, K.F.1
  • 20
    • 32944471001 scopus 로고    scopus 로고
    • So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics
    • Williams, J.A. et al.: So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J Clin Pharmacol 2006, 46:258-264.
    • (2006) J Clin Pharmacol , vol.46 , pp. 258-264
    • Williams, J.A.1
  • 21
    • 0037812407 scopus 로고    scopus 로고
    • Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience
    • Blesch, K.S. et al.: Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience. Invest New Drugs 2003, 21:195-223.
    • (2003) Invest New Drugs , vol.21 , pp. 195-223
    • Blesch, K.S.1
  • 22
    • 0034458680 scopus 로고    scopus 로고
    • Current methodologies used for evaluation of intestinal permeability and absorption
    • Balimane, P.V. et al.: Current methodologies used for evaluation of intestinal permeability and absorption. J Pharmacol Toxicol Methods 2000, 44:301-312.
    • (2000) J Pharmacol Toxicol Methods , vol.44 , pp. 301-312
    • Balimane, P.V.1
  • 23
    • 0142010701 scopus 로고    scopus 로고
    • Drug metabolism and drug interactions: application and clinical value of in vitro models
    • Venkatakrishnan, K. et al.: Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 2003, 4:423-459.
    • (2003) Curr Drug Metab , vol.4 , pp. 423-459
    • Venkatakrishnan, K.1
  • 24
    • 1542344547 scopus 로고    scopus 로고
    • Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors
    • Proctor, N.J. et al.: Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 2004, 34:151-178.
    • (2004) Xenobiotica , vol.34 , pp. 151-178
    • Proctor, N.J.1
  • 25
    • 0034807892 scopus 로고    scopus 로고
    • Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus
    • Tucker, G.T. et al.: Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 2001, 18:1071-1080.
    • (2001) Pharm Res , vol.18 , pp. 1071-1080
    • Tucker, G.T.1
  • 26
    • 0017335453 scopus 로고
    • Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance
    • Rane, A. et al.: Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 1977, 200:420-424.
    • (1977) J Pharmacol Exp Ther , vol.200 , pp. 420-424
    • Rane, A.1
  • 27
    • 0029950964 scopus 로고    scopus 로고
    • Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics
    • Iwatsubo, T. et al.: Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 1996, 17:273-310.
    • (1996) Biopharm Drug Dispos , vol.17 , pp. 273-310
    • Iwatsubo, T.1
  • 28
    • 13244287685 scopus 로고    scopus 로고
    • 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions
    • Rostami-Hodjegan, A. and Tucker, G.: 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discovery Today: Technologies 2004, 1:441-448.
    • (2004) Drug Discovery Today: Technologies , vol.1 , pp. 441-448
    • Rostami-Hodjegan, A.1    Tucker, G.2
  • 29
    • 0037216664 scopus 로고    scopus 로고
    • Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations
    • Visser, S.A. et al.: Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J Pharmacol Exp Ther 2003, 304:88-101.
    • (2003) J Pharmacol Exp Ther , vol.304 , pp. 88-101
    • Visser, S.A.1
  • 30
    • 0034005059 scopus 로고    scopus 로고
    • Mechanism-based modeling of functional adaptation upon chronic treatment with midazolam
    • Cleton, A. et al.: Mechanism-based modeling of functional adaptation upon chronic treatment with midazolam. Pharm Res 2000, 17:321-327.
    • (2000) Pharm Res , vol.17 , pp. 321-327
    • Cleton, A.1
  • 31
    • 0031936583 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor
    • Cox, E.H. et al.: Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther 1998, 284:1095-1103.
    • (1998) J Pharmacol Exp Ther , vol.284 , pp. 1095-1103
    • Cox, E.H.1
  • 32
    • 0141525465 scopus 로고    scopus 로고
    • Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol
    • Liu, J. et al.: Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003, 74:372-379.
    • (2003) Clin Pharmacol Ther , vol.74 , pp. 372-379
    • Liu, J.1
  • 33
    • 0038433342 scopus 로고    scopus 로고
    • A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization
    • Bezzina, C.R. et al.: A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res 2003, 59:27-36.
    • (2003) Cardiovasc Res , vol.59 , pp. 27-36
    • Bezzina, C.R.1
  • 34
    • 0035553086 scopus 로고    scopus 로고
    • Drug target pharmacogenomics: an overview
    • Johnson, J.A.: Drug target pharmacogenomics: an overview. Am J Pharmacogenomics 2001, 1:271-281.
    • (2001) Am J Pharmacogenomics , vol.1 , pp. 271-281
    • Johnson, J.A.1
  • 35
    • 0037421590 scopus 로고    scopus 로고
    • Pharmacogenomics-drug disposition, drug targets, and side effects
    • Evans, W.E., McLeod, H.L.: Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003, 348:538-549.
    • (2003) N Engl J Med , vol.348 , pp. 538-549
    • Evans, W.E.1    McLeod, H.L.2
  • 36
    • 33745130722 scopus 로고    scopus 로고
    • Prediction of in vivo drug clearance from in vitro data I: impact of inter-individual variability
    • Howgate, E.M. et al.: Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica 2006, 36:473-497.
    • (2006) Xenobiotica , vol.36 , pp. 473-497
    • Howgate, E.M.1
  • 37
    • 33746803672 scopus 로고    scopus 로고
    • Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children
    • Johnson, T.N. et al.: Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006, 45:931-956.
    • (2006) Clin Pharmacokinet , vol.45 , pp. 931-956
    • Johnson, T.N.1
  • 38
    • 34250663402 scopus 로고    scopus 로고
    • The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies-CYP2C9 and Warfarin as an example
    • in press
    • Dickison, G.L. et al.: The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies-CYP2C9 and Warfarin as an example. Brit J Clin Pharmacol 2007, in press.
    • (2007) Brit J Clin Pharmacol
    • Dickison, G.L.1
  • 39
    • 33846450220 scopus 로고    scopus 로고
    • Clinical trial simulation of the effect of CYP2D6 polymorphism on the antitussive response to dextromethorphan
    • Dickinson, G.L. et al.: Clinical trial simulation of the effect of CYP2D6 polymorphism on the antitussive response to dextromethorphan. J PharmSci 2007, 47:175-186.
    • (2007) J PharmSci , vol.47 , pp. 175-186
    • Dickinson, G.L.1
  • 40
    • 2942717008 scopus 로고    scopus 로고
    • Estimation of standard liver volume for liver transplantation in the Korean population
    • Yu, H.C. et al.: Estimation of standard liver volume for liver transplantation in the Korean population. Liver Transpl 2004, 10:779-783.
    • (2004) Liver Transpl , vol.10 , pp. 779-783
    • Yu, H.C.1
  • 41
    • 33745181651 scopus 로고    scopus 로고
    • Prediction of in vivo drug clearance from in vitro data II: potential inter-ethnic differences
    • Inoue, S. et al.: Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. Xenobiotica 2006, 36:499-513.
    • (2006) Xenobiotica , vol.36 , pp. 499-513
    • Inoue, S.1
  • 42
    • 0036914221 scopus 로고    scopus 로고
    • Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
    • Scordo, M.G. et al.: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002, 72:702-710.
    • (2002) Clin Pharmacol Ther , vol.72 , pp. 702-710
    • Scordo, M.G.1
  • 43
    • 0037374422 scopus 로고    scopus 로고
    • Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients
    • Takahashi, H. et al.: Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003, 73:253-263.
    • (2003) Clin Pharmacol Ther , vol.73 , pp. 253-263
    • Takahashi, H.1
  • 44
    • 1542346414 scopus 로고    scopus 로고
    • Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin
    • Kamali, F. et al.: Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004, 75:204-212.
    • (2004) Clin Pharmacol Ther , vol.75 , pp. 204-212
    • Kamali, F.1
  • 45
    • 17944366735 scopus 로고    scopus 로고
    • Interindividual variability in sensitivity to warfarin-nature or nurture?
    • Loebstein, R. et al.: Interindividual variability in sensitivity to warfarin-nature or nurture? Clin Pharmacol Ther 2001, 70:159-164.
    • (2001) Clin Pharmacol Ther , vol.70 , pp. 159-164
    • Loebstein, R.1
  • 46
    • 0842308834 scopus 로고    scopus 로고
    • Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin
    • Khan, T. et al.: Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 2004, 124:348-354.
    • (2004) Br J Haematol , vol.124 , pp. 348-354
    • Khan, T.1
  • 47
    • 3042575861 scopus 로고    scopus 로고
    • Warfarin dosing and cytochrome P450 2C9 polymorphisms
    • Joffe, H.V. et al.: Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004, 91:1123-1128.
    • (2004) Thromb Haemost , vol.91 , pp. 1123-1128
    • Joffe, H.V.1
  • 48
    • 1842475297 scopus 로고    scopus 로고
    • Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients
    • Siguret, V. et al.: Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients. Rev Med Interne 2004, 25:271-274.
    • (2004) Rev Med Interne , vol.25 , pp. 271-274
    • Siguret, V.1
  • 49
    • 0036194038 scopus 로고    scopus 로고
    • The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin
    • Tabrizi, A.R. et al.: The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 2002, 194:267-273.
    • (2002) J Am Coll Surg , vol.194 , pp. 267-273
    • Tabrizi, A.R.1
  • 50
    • 11244284872 scopus 로고    scopus 로고
    • Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism
    • King, B.P. et al.: Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004, 14:813-822.
    • (2004) Pharmacogenetics , vol.14 , pp. 813-822
    • King, B.P.1
  • 51
    • 1542346407 scopus 로고    scopus 로고
    • CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy
    • Peyvandi, F. et al.: CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 2004, 75:198-203.
    • (2004) Clin Pharmacol Ther , vol.75 , pp. 198-203
    • Peyvandi, F.1
  • 52
    • 0033694203 scopus 로고    scopus 로고
    • Genetic modulation of oral anticoagulation with warfarin
    • Margaglione, M. et al.: Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000, 84:775-778.
    • (2000) Thromb Haemost , vol.84 , pp. 775-778
    • Margaglione, M.1
  • 53
    • 0037012465 scopus 로고    scopus 로고
    • Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
    • Higashi, M.K. et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama 2002, 287:1690-1698.
    • (2002) Jama , vol.287 , pp. 1690-1698
    • Higashi, M.K.1
  • 54
    • 28144454744 scopus 로고    scopus 로고
    • Several-fold increase in risk of overanticoagulation by CYP2C9 mutations
    • Lindh, J.D. et al.: Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 2005, 78:540-550.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 540-550
    • Lindh, J.D.1
  • 55
    • 23044440450 scopus 로고    scopus 로고
    • The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
    • Sconce, E.A. et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005, 106:2329-2333.
    • (2005) Blood , vol.106 , pp. 2329-2333
    • Sconce, E.A.1
  • 56
    • 33645849823 scopus 로고    scopus 로고
    • Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements
    • Aquilante, C.L. et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006, 79:291-302.
    • (2006) Clin Pharmacol Ther , vol.79 , pp. 291-302
    • Aquilante, C.L.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.